POLIVY is designed to work differently from traditional chemotherapies in patients with R/R DLBCL

POLIVY (polatuzumab vedotin-piiq) is an FDA-approved treatment for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have already received at least 2 prior therapies. It is used in combination with 2 other cancer treatments: bendamustine and a rituximab product (BR).

POLIVY received an accelerated approval from the FDA. This conditional approval helps patients get earlier access to a promising drug while the company continues to conduct clinical trials to establish how the drug works.

Learn about how POLIVY was designed to treat relapsed or refractory DLBCL.

Talk to your doctor about possible side effects. Please also see Possible Side Effects and the full Prescribing Information for additional Important Safety Information